FTC Paxil Subpoena Documents Protected By Attorney-Client Privilege – Court
Executive Summary
The Federal Trade Commission's investigations into late-listed pharmaceutical patents could face a hurdle in the attorney-client privilege, an appellate court decision suggests
You may also be interested in...
Paxil Late-Listed Patents Are Questionable For Orange Book Listing – FTC
Generic versions of Paxil are being held up by patents whose listing in the "Orange Book" is questionable, the Federal Trade Commission's generic drug report states
Paxil Late-Listed Patents Are Questionable For Orange Book Listing – FTC
Generic versions of Paxil are being held up by patents whose listing in the "Orange Book" is questionable, the Federal Trade Commission's generic drug report states
GSK Supports Waxman/Hatch Trade: Drop Bolar, Remove 30-Month Stays
GlaxoSmithKline supports a legislative deal to change the 30-month stays on generic approvals during patent litigation in return for having generic firms give up their right to do development work on drugs prior to patent expiration